Welcome to our dedicated page for Azitra SEC filings (Ticker: AZTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Azitra Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on precision dermatology. Recent disclosures cover proxy materials for annual and special stockholder meetings, shareholder voting procedures, board and governance matters, and meeting-status updates filed on Form 8-K.
Azitra's SEC reports also describe material agreements and capital-structure changes, including private placement securities, Series A preferred stock and Series B and Series C warrants. Other filings address furnished financial results, pipeline business updates, use of financing proceeds for research and development and working capital, and NYSE American continued-listing compliance matters tied to stockholders' equity standards.
Azitra, Inc. disclosure: Dauntless Investment Group, LLC filed a Schedule 13G reporting beneficial ownership of 5,804,636 shares of Azitra common stock, representing 9.58% of the class. The filer reports sole dispositive power over these shares and no voting power. The filing lists the filer as a "Single Family Office/Passive Investor" and is signed by the company's CFO on 06/25/2026.
Azitra, Inc.’s President and Chief Executive Officer, Francisco D. Salva, filed a Schedule 13D reporting a significant personal stake in the company. As of June 24, 2026, he beneficially owned 5,421,039 shares of common stock, representing 9.99% of the 52,907,666 shares outstanding.
His beneficial ownership includes 22,241 Incentive Stock Options and 1,334,748 shares underlying warrants that are exercisable within 60 days. It excludes 6,793,352 warrant shares that are not issuable within 60 days and are subject to a beneficial ownership limitation. Salva states he holds the securities for investment purposes but may buy or sell more shares depending on conditions.
Azitra, Inc. ownership disclosure: Stonepine entities and Jon M. Plexico report shared beneficial ownership of 1,744,339 shares of Common Stock, representing 9.9% of the class. The filing states the percentage "is giving effect to the 9.99% beneficial ownership limitation" and uses May 12, 2026 as the outstanding-share anchor of 16,192,438 shares.
The reporting persons note their holdings comprise 475,923 shares of Common Stock, Series A Preferred convertible into 27,107,210 shares, and Warrants to acquire 54,214,420 shares, each subject to a 9.99% beneficial ownership cap. Signatures show Jon M. Plexico as the reporting signatory.
Azitra, Inc. President and CEO Francisco D. Salva converted preferred stock into common shares. On June 16, 2026, he converted 500 shares of Series A Convertible Non-Redeemable Preferred Stock into 4,064,050 shares of common stock for no additional consideration, as provided in the Series A Certificate of Designations and subject to Beneficial Ownership Limitations. Following the automatic conversion, his reported beneficial ownership is 4,086,291 shares of common stock, which includes 22,241 incentive stock options exercisable within 60 days of June 16, 2026.
Azitra, Inc. filed a current report highlighting a CEO letter that outlines a strategic reorientation and growth plan for 2026 and beyond. The company completed a March financing of $10.5 million plus up to $21 million from warrant exercises, enabling expansion beyond therapeutics.
New initiatives include ATR-COSF, a recombinant filaggrin cosmetic ingredient targeting fine lines and wrinkles, with a clinical study expected to complete in late 2026 and potential partnering or commercialization as soon as 2027. Azitra is also launching recombinant protein programs using in-licensed microbial engineering technologies, initially focused on TEV protease and T7 RNA polymerase for research and manufacturing markets.
Within its existing pipeline, the company continues enrolling patients in ATR-04 for EGFR inhibitor-associated rash and added MD Anderson Cancer Center as a clinical site. Azitra plans to pause further enrollment in its ATR-12 Netherton syndrome trial to conserve capital and redirect funds to nearer-term cosmetic initiatives, emphasizing financial discipline and multiple potential paths to long-term value creation.
Azitra, Inc. reported results from its 2026 annual stockholder meeting and a major change to its charter. The company filed a certificate of amendment in Delaware to raise its authorized common stock from 200,000,000 to 750,000,000 shares, increasing overall authorized capital.
Stockholders elected four directors and authorized the board to implement one or more reverse stock splits. They also approved NYSE American–required approvals for potential issuances above 19.99% of outstanding common stock tied to a November 2025 securities purchase agreement with Alumni Capital LP and a March 18, 2026 financing involving Series A Preferred Stock and Series B and C Warrants.
Investors ratified Grassi & Co., CPAs, P.C. as auditor and approved an adjournment proposal, but did not approve an amendment to increase the share reserve under the 2023 Stock Incentive Plan.
Azitra, Inc. adjourned its 2026 annual meeting of stockholders after failing to reach a quorum. A quorum would have required shares representing 33 1/3% of the common stock entitled to vote, but only about 17% of eligible shares were represented by proxy.
The meeting, originally convened on June 4, 2026, will reconvene virtually on June 15, 2026, at 11:00 a.m. Eastern Time via www.proxydocs.com/AZTR. Stockholders of record as of April 24, 2026 remain entitled to vote, and previously submitted proxies remain valid unless changed.
Azitra’s press release explains that stockholders can vote or change prior votes by mail, internet, telephone, or during the reconvened virtual meeting, following instructions in the definitive proxy statement filed on May 8, 2026.
Azitra, Inc. is postponing the business of its 2026 annual stockholders’ meeting due to a minor administrative delay in mailing proxy materials. The company will open the meeting on June 4, 2026 at 11:00 a.m. Eastern Time and immediately adjourn it without conducting other business.
The annual meeting will reconvene virtually on June 15, 2026 at 11:00 a.m. Eastern Time at www.proxydocs.com/AZTR. The record date remains April 24, 2026, and the proposals to be voted on are unchanged. Stockholders who already voted and do not wish to change their vote do not need to take further action.
Azitra, Inc. is registering 255,699,381 shares of common stock for resale by existing investors. These shares come from the conversion of 10,485 shares of Series A preferred stock into 85,223,129 conversion shares and the potential exercise of Series B and C warrants for 170,466,252 warrant shares, including related pre-funded warrants. Azitra is not selling shares in this offering and will not receive proceeds from stockholder resales, though full cash exercise of the warrants could bring in approximately $21 million. Common stock outstanding was 16,192,438 shares as of May 19, 2026, and would increase to 271,865,819 shares if all preferred, warrants and pre-funded warrants are fully exercised. The company reports a going concern warning, limited cash resources, significant potential dilution, and an existing NYSE American listing compliance plan.